Engineering antibodies for clinical applications

Research output: Contribution to journalReview article

80 Citations (Scopus)

Abstract

Molecular engineering has contributed immensely to the clinical success of antibodies in recent years. The modular structure of antibodies has permitted their modification in numerous ways, to meet various clinical requirements. With the help of antibody engineering, it has been possible to modify the molecular size, pharmacokinetics, immunogenicity, binding affinity, specificity and effector function of antibodies. In addition, fusion proteins of antibodies with various proteins and peptides have yielded targeted biological modifiers, toxins and imaging agents. This review focuses on the recent trends in antibody engineering for improving their clinical utility.

Original languageEnglish (US)
Pages (from-to)307-316
Number of pages10
JournalTrends in Biotechnology
Volume25
Issue number7
DOIs
StatePublished - Jul 1 2007

Fingerprint

Biomedical Engineering
Antibodies
Biological Toxins
Proteins
Pharmacokinetics
Peptides
Fusion reactions
Imaging techniques

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering

Cite this

Engineering antibodies for clinical applications. / Jain, Maneesh; Kamal, Neel; Batra, Surinder Kumar.

In: Trends in Biotechnology, Vol. 25, No. 7, 01.07.2007, p. 307-316.

Research output: Contribution to journalReview article

@article{43358e51cf2f4f708fcf741c98d9984a,
title = "Engineering antibodies for clinical applications",
abstract = "Molecular engineering has contributed immensely to the clinical success of antibodies in recent years. The modular structure of antibodies has permitted their modification in numerous ways, to meet various clinical requirements. With the help of antibody engineering, it has been possible to modify the molecular size, pharmacokinetics, immunogenicity, binding affinity, specificity and effector function of antibodies. In addition, fusion proteins of antibodies with various proteins and peptides have yielded targeted biological modifiers, toxins and imaging agents. This review focuses on the recent trends in antibody engineering for improving their clinical utility.",
author = "Maneesh Jain and Neel Kamal and Batra, {Surinder Kumar}",
year = "2007",
month = "7",
day = "1",
doi = "10.1016/j.tibtech.2007.05.001",
language = "English (US)",
volume = "25",
pages = "307--316",
journal = "Trends in Biotechnology",
issn = "0167-7799",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Engineering antibodies for clinical applications

AU - Jain, Maneesh

AU - Kamal, Neel

AU - Batra, Surinder Kumar

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Molecular engineering has contributed immensely to the clinical success of antibodies in recent years. The modular structure of antibodies has permitted their modification in numerous ways, to meet various clinical requirements. With the help of antibody engineering, it has been possible to modify the molecular size, pharmacokinetics, immunogenicity, binding affinity, specificity and effector function of antibodies. In addition, fusion proteins of antibodies with various proteins and peptides have yielded targeted biological modifiers, toxins and imaging agents. This review focuses on the recent trends in antibody engineering for improving their clinical utility.

AB - Molecular engineering has contributed immensely to the clinical success of antibodies in recent years. The modular structure of antibodies has permitted their modification in numerous ways, to meet various clinical requirements. With the help of antibody engineering, it has been possible to modify the molecular size, pharmacokinetics, immunogenicity, binding affinity, specificity and effector function of antibodies. In addition, fusion proteins of antibodies with various proteins and peptides have yielded targeted biological modifiers, toxins and imaging agents. This review focuses on the recent trends in antibody engineering for improving their clinical utility.

UR - http://www.scopus.com/inward/record.url?scp=34250177619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250177619&partnerID=8YFLogxK

U2 - 10.1016/j.tibtech.2007.05.001

DO - 10.1016/j.tibtech.2007.05.001

M3 - Review article

VL - 25

SP - 307

EP - 316

JO - Trends in Biotechnology

JF - Trends in Biotechnology

SN - 0167-7799

IS - 7

ER -